Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Therapeutic Drug Carrier Systems
Factor de Impacto: 2.9 Factor de Impacto de 5 años: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Imprimir: 0743-4863
ISSN En Línea: 2162-660X

Volumen 37, 2020 Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v24.i5.20
pages 445-492

Optimizing Drug Delivery for Enhancing Therapeutic Efficacy of Recombinant Human Endostatin in Cancer Treatment

Fuguo Xu
Department of Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
Qingyong Ma
Department of Hepatobiliary Surgery, First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China
Huanchen Sha
Department of Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China


Recombinant human endostatin (rhEndostatin) is uniquely able to target neovascular endothelial cells (ECs) and has the potential for antiangiogenetic and antitumor activities. In this review, we explore experimental approaches and clinical trials focusing on drug delivery of endostatin. Continued endostatin therapy can maintain tumors in a state of dormancy, and no signs of drug-induced resistance have been observed. Prolonged delivery of endostatin may be achieved by using pumps (mini-osmotic pumps) or cell encapsulation systems. The largest benefit from rhEndostatin is expected when drug delivery of rhEndostatin is begun as early as possible. Although endostatin has shown promise in controlling tumor neovasculature, a major problem in pharmacotherapy is the side effects of constant drug administration and the limited half-life of antiangiogenic proteins. Gene therapy offers the advantages of maximizing cost effectiveness and maintaining sustained levels of antiangiogenic factors, which may enhance antitumor efficacy. Therefore, we have investigated recent advances in gene delivery of endostatin for cancer treatment. In recent years, preclinical and clinical data have demonstrated the synergistic effects of rhEndostatin combined with other therapies on inhibiting growth of malignant tumors, with minimal toxicity. rhEndostatin has not been proven to prolong the survival rate of patients challenged with cancer when used as single therapy. Thus, we suggest that the combination of rhEndostatin with chemotherapy, radiotherapy, and biotherapy (i.e., fusion protein, molecular-targeted therapy on cancers, etc.) might provide an optimal strategy for cancer treatment.

Articles with similar content:

The Wonders of Silk Fibroin Biomaterials in the Treatment of Breast Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.28, 2018, issue 2
Terin Adali, Pinar Tulay, Nanyak Galam
Tumor Hypoxia: A Key Determinant of Microenvironment Hostility and a Major Checkpoint during the Antitumor Response
Critical Reviews™ in Immunology, Vol.38, 2018, issue 6
Hussam H. Nawafleh, Stéphanie Buart, Rania Faouzi Zaarour, Stéphane Terry, Amirtharaj Francis, Prathibha Prasad, Nagwa Ahmed Zeinelabdin, Salem Chouaib, Goutham Hassan Venkatesh
Emerging Role of Vesicular Carriers for Therapy of Visceral Leishmaniasis: Conventional versus Novel
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.27, 2010, issue 6
Navneet Kumar, Suresh P. Vyas, Anuradha Dube, Swati Gupta
New Prospectives of Prostate Cancer Gene Therapy: Molecular Targets and Animal Models
Critical Reviews™ in Eukaryotic Gene Expression, Vol.11, 2001, issue 1-3
Chia-Ling Hsieh, Leland W. K. Chung
Cellular Actions and Signaling by Endostatin
Critical Reviews™ in Eukaryotic Gene Expression, Vol.12, 2002, issue 3
Seth L. Alper, Vikas P. Sukhatme, Ramam Ramchandran, Jun-ichi Hanai, S. Ananth Karumanchi